Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ortho-hydroxybenzoic acid or derivative doai
Reexamination Certificate
1999-08-17
2001-08-28
Jarvis, William R. A. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ortho-hydroxybenzoic acid or derivative doai
C424S401000
Reexamination Certificate
active
06281203
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to a cosmetic and/or dermatological composition and to the use of this composition for combating ageing of the skin, and for treating skin disorders.
2. Discussion of the Background
Beta-hydroxy acids and in particular, salicylic acid and its derivatives, have been known as keratolytic agents for treating acne and as antiageing agents in cosmetic and/or dermatological compositions. Thus, document WO-A-93/10756 describes the use of a composition based on salicylic acid for treating wrinkles and the documents FR-A-2,581,542 and EP-A-378,936 describe the use of salicylic acid derivatives for treating acne and the signs of ageing.
Salicylic acid and its derivatives are of great interest given their biological effects on the skin, particularly in treating the principal clinical signs of skin ageing which are fine lines and wrinkles, the disorganization of the“grain” of the skin, the modification of the complexion of the skin and the loss of skin firmness and tone. Salicylic acid derivatives have a higher keratolytic activity and effective bacteriostatic activity compared to salicylic acid.
Unfortunately, the use of these agents can cause prickling, itching and pulling after their application, which can lead to great discomfort. Therefore, the use of these compounds for treating persons with sensitive skin is not recommended.
Consequently, the need remains for a cosmetic and/or dermatological composition based on such compounds, which does not exhibit the disadvantages of the prior art.
SUMMARY OF THE INVENTION
It is an object of this invention to prepare compositions for treating skin to combat the effects of ageing.
It is another object of the invention to prepare compositions suitable for treating skin disorders.
It is another object of the invention to devise a process for treating the human body for cosmetic and dermatological purposes.
The applicant has found, unexpectedly, that the tolerance of individuals to salicylic acid and its derivatives can be increased by incorporating them into an oil-in-water (O/W) emulsion containing a mixture of at least one fatty ester of glucose or an alkylglucose and at least one oxyalkylenated ether of a fatty ester of glucose or an alkylglucose.
The present invention is directed to a cosmetic and/or dermatological composition in the form of an oil-in-water emulsion, which contains (i) salicylic acid and/or at least one salicylic acid derivative, (ii) at least one ester of a fatty acid and glucose and/or an alkylglucose, and (iii) at least one oxyalkylenated ether of a fatty acid ester of glucose and/or an alkylglucose.
The combination of a fatty acid ester of (alkyl)glucose and an oxyalkylenated ether of a fatty acid ester of (alkyl)glucose unexpectedly provides a composition which is perfectly tolerated when applied to the face or skin of the human body.
DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION
The fatty chain in the ester of a fatty acid and an (alkyl)glucose and in the oxyalkylenated ether of a fatty acid ester of an (alkyl)glucose may contain from about 8 to about 30 carbon atoms and more particularly from about 10 to about 22 carbon atoms.
Suitable esters of a fatty acid and glucose or an alkylglucose, include the fatty esters of methylglucoside such as the diester of methylglucoside and oleic acid (CTFA name: methyl glucose dioleate); the mixed ester of methylglucoside and an oleic acid/hydroxystearic acid mixture (CTFA name: methyl glucose dioleate/hydroxystearate); the ester of methylglucoside and isostearic acid (CTFA name: methyl glucose isostearate); the ester of methylglucoside and lauric acid (CTFA name: methyl glucose laurate); the ester of methylglucoside and isostearic acid (CTFA name: methyl glucose isostearate); a mixture of the monoester and diester of methylglucoside and isostearic acid (CTFA name: methyl glucose sesquiisostearate); a mixture of the monoester and diester of methylglucoside and stearic acid (CTFA name: methyl glucose sesquistearate) and a product marketed under the name Glucate SS by the company Amerchol. Mixtures of these esters are also contemplated.
Preferably, the ester of a fatty acid and glucose or alkylglucose is introduced into the oily phase of the emulsion and in a quantity sufficient to achieve the desired result. This amount may range from about 0.1% to about 10% by weight, preferably from about 1% to about 3% by weight relative to the total weight of the composition.
The oxyalkylenated ether of a fatty acid and glucose or alkylglucose may contain from about 10 to about 100 oxyalkylenated groups (or moles of an alkylene oxide such as ethylene oxide, propylene oxide or mixtures thereof), preferably from about 20 to about 40 oxyalkylenated groups. Suitable ethers of a fatty acid and glucose or alkylglucose, include, for example, oxyethylenated ethers of a fatty acid and methylglucose, such as a polyethylene glycol ether of a diester of methylglucose and stearic acid containing about 20 moles of ethylene oxide (CTFA name: PEG-20 methyl glucose distearate marketed under the name Glucam E-20 distearate by the company Amerchol); a polyethylene glycol ether of a mixture of the monoester and diester of methylglucose and stearic acid containing about 20 moles of ethylene oxide (CTFA name: PEG-20 methyl glucose sesquistearate marketed under the name Glucamate SSE-20 by the company Amerchol and under the name Grillocose PSE-20 by the company Goldschmidt). Mixtures of these oxyalkylenated ethers can be used.
Preferably, the oxyalkylenated ether is introduced into the aqueous phase of the emulsion and in a quantity sufficient to achieve the desired result. The oxyalkylenated ether may be used in an amount of from about 0.1% to about 10% by weight, preferably from about 1% to about 3% by weight relative to the total weight of the composition.
The compositions of the invention also contain salicylic acid and/or one or more salicylic acid derivatives. Suitable salicylic acid derivatives include those of formula (I) or a salt thereof:
in which:
R
1
represents hydrogen or a saturated, linear, branched or cyclized aliphatic hydrocarbon group or an alkoxy, ester or ketoxy group, or an unsaturated group having at least one conjugated or unconjugated double bond, wherein these groups may contain from 1 to about 22 carbon atoms and may be substituted with at least one substituent chosen from halogen atoms, the trifluoromethyl group, hydroxyl groups in a free form or esterifled by an acid having from 1 to about 6 carbon atoms or a carboxyl group, which is free or esterified by a lower alcohol having from 1 to about 6 carbon atoms;
R
2
represents a hydroxyl group or an ester of formula (II):
where R
4
represents a saturated aliphatic group or an alkenyl group having from 1 to about 18 carbon atoms;
R
3
represents hydrogen or a saturated or unsaturated linear or branched chain having from 2 to about 30 carbon atoms, optionally containing one or more substituents such as those listed above. Alkyl and alkenyl radicals containing from 2 to about 30 carbon atoms are suitable and are optionally substituted. The preferred substituent is a hydroxyl radical.
When R
3
is hydrogen, one can use salts of the compounds of formula (I), particularly salts obtained by reaction with a base. Suitable bases include alkali metal hydroxides (sodium and potassium hydroxides), ammonium hydroxide, organic bases such as primary, secondary, tertiary or cyclic organic amines, and amino acids. Specific examples of bases include glycine, lysine, arginine, taurine, histidine, alanine, valine, cysteine, trihydroxymethylaminomethane (TRISTA) and triethanolamine.
According to a preferred embodiment of the invention, compositions are prepared using derivatives of formula (I) where R
1
contains at least 4 carbon atoms. For example, R
1
may be a saturated linear alkyl or alkoxy radical having from 4 to 11 carbon atoms.
Derivatives of formula (I) in which R
2
is hydroxyl and R
3
is hydrogen, include 5-n-octanoylsalicylic acid (CTFA name: Capryloyl
DeLambre Patricia
Touzan Philippe
Jarvis William R. A.
Kim Vickie
L'Oreal
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Cosmetic and/or dermatological composition containing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cosmetic and/or dermatological composition containing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cosmetic and/or dermatological composition containing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2549174